But not without adverse events
Abbreviations GLP1-RA: Glucagon like peptide-1 receptor agonist ASCVD: Atherosclerotic cardiovascular disease MACE: Major adverse cardiovascular events NNT: Numbers Needed to Treat MI: Myocardial Infarction CVD: Cardiovascular Disease SGLT2i: Sodium-glucose cotransporter-2 inhibitors LEADER: Liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results T2DM: Type 2 Diabetes mellitus SELECT: Semaglutide effects on cardiovascular outcomes in people with overweight or obesity PREVENT: Predicting risk of cardiovascular disease events HF: Heart Failure PRISMA: Preferred reporting items for systematic review and meta-analyses RCT: Randomized controlled trial BMI: Body mass index RR: Risk ratio NNTB: Numbers needed to benefit NNTH: Number needed to harm ROB-2: Cochrane risk of bias 2 (ROB-2) tool FLOW: Evaluate renal function with semaglutide once weekly References Federation WH

Other Ingredients: Diluent (Microcrystalline Cellulose), Diluent (Lactose), Dis-integrant (Croscarmellose Sodium), Stabilizer (Polyvinyl Pyrrolidone), Antisticking agent (Magnesium Stearate), Coating agent (Hydroxypropyl Methyl Cellulose), Vehicle (Polyethylene Glycol), Glidant (Talc), Coating agent (Ethyl Cellulose) & Colours (Titanium Dioxide & Ponceau 4R)
What are the possible drawbacks of taking GLP-1 or dual GLP-1/GIP agonists for 10 to 20 years
Developed by Eli Lilly, retatrutide is in late-stage clinical trials but not yet FDA-approved